PPP2CA encodes the alpha isoform of protein phosphatase 2A (PP2A), a major serine/threonine phosphatase that constitutes approximately 1% of total cellular proteins and accounts for the majority of phosphatase activity in the brain [@pp2a_neurodegeneration_2009]. PP2A is a heterotrimeric enzyme consisting of a catalytic subunit (C), a structural subunit (A), and one of many regulatory B subunits that determine substrate specificity, subcellular localization, and enzyme activity [@pp2a_structure_1999]. This gene is located on chromosome 5q31.1 and is essential for numerous cellular processes including cell cycle progression, signal transduction, protein synthesis, metabolism, and neuronal function. In the brain, PP2A plays critical roles in tau dephosphorylation, apoptosis regulation, synaptic plasticity, and neurodevelopment, making it a key player in neurodegenerative disease pathogenesis [@tau_hyperphosphorylation_2005].
| Protein Phosphatase 2 Catalytic Subunit Alpha | |
|---|---|
| Gene Symbol | PPP2CA |
| Full Name | Protein phosphatase 2 catalytic subunit alpha |
| Chromosome | 5q31.1 |
| NCBI Gene ID | [5515](https://www.ncbi.nlm.nih.gov/gene/5515) |
| OMIM | 176915 |
| Ensembl ID | ENSG00000141837 |
| UniProt ID | [P67775](https://www.uniprot.org/uniprot/P67775) |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, FTLD, Cognitive Impairment |
The PP2A catalytic subunit (PP2Ac) is a 36 kDa protein belonging to the phosphoprotein phosphatase (PPP) family. The crystal structure reveals a conserved catalytic core with active site residues essential for dephosphorylation of serine/threonine residues [@pp2a_structure_1999]. Two isoforms exist (alpha and beta), with PPP2CA being the predominant isoform in most tissues, including the brain. The catalytic subunit contains critical residues for metal ion binding (Mn²⁺ and Mg²⁺), which are required for phosphatase activity. Post-translational modifications including phosphorylation, methylation, and glycosylation regulate PP2Ac function [@b subunit_2011].
PP2A functions as a heterotrimeric complex consisting of:
Over 15 different regulatory B subunits have been identified, classified into four families (B, B', B'', and B'''), each with multiple isoforms. In neurons, specific B subunits like B56α (PPP2R5A) and B55α (PPP2R2A) are highly expressed and regulate synaptic plasticity and cell survival pathways [@synapse_2014].
In Alzheimer's disease (AD), PP2A activity is significantly reduced in the brain, contributing to tau hyperphosphorylation and neurofibrillary tangle formation [@tau_hyperphosphorylation_2005]. PP2A is the primary phosphatase responsible for dephosphorylating tau at multiple sites that are hyperphosphorylated in AD, including Ser199, Thr205, Ser396, and Ser404. Reduced PP2A activity in AD brains correlates with:
Studies have shown that PP2A methylation is altered in AD brains, leading to reduced enzyme activity [@methylation_2010]. The methyltransferase LEU287 and phosphatase LCMT1, which regulate PP2A methylation, are downregulated in AD, providing a molecular mechanism for PP2A dysfunction.
In Parkinson's disease (PD), PP2A plays a critical role in regulating alpha-synuclein phosphorylation at Ser129, which influences its aggregation, toxicity, and Lewy body formation [@alpha_syn_phosphorylation_2012]. PP2A dephosphorylates alpha-synuclein at Ser129, and reduced PP2A activity promotes pathogenic aggregation [@lewy_bodies_2013]. PP2A also:
Activation of PP2A has demonstrated neuroprotective effects in PD models, reducing dopaminergic neuron loss and improving behavioral outcomes [@neuroprotection_2017].
PP2A dysfunction is also implicated in frontotemporal lobar degeneration (FTLD), where tau pathology is a key feature. Altered PP2A activity contributes to tau hyperphosphorylation and aggregation in FTLD subtypes [@ftld_2018].
PPP2CA is ubiquitously expressed with high levels in brain tissue. Within the brain, PP2A is expressed in:
The heterogeneous distribution of regulatory B subunits determines PP2A subcellular localization and substrate specificity in different neuronal populations [@b subunit_2011]. PP2A regulates synaptic plasticity, learning, and memory through modulation of AMPA receptor trafficking, NMDA receptor signaling, and long-term potentiation (LTP) [@synapse_2014].
PP2A activators are being developed as therapeutic agents for tauopathies including AD and PSP:
PP2A activity in cerebrospinal fluid (CSF) shows promise as a biomarker for AD diagnosis and progression [@biomarker_2019]. Reduced CSF PP2A activity correlates with cognitive impairment and brain atrophy in AD patients.
PP2A catalytic subunit is phosphorylated at multiple sites:
Leucine carboxyl methyltransferase 1 (LCMT1) methylates PP2A at Leu309, which is essential for holoenzyme assembly. This modification is reversible and regulated by PME-1 (phosphatase methylesterase-1).
Okadaic acid and microcystin are potent PP2A inhibitors produced by marine cyanobacteria and freshwater blooms, respectively. These toxins have been used extensively to study PP2A function in neurodegeneration models [@okadaic_2004].
PP2A activity is sensitive to metal ion imbalance, which is relevant in neurodegeneration [@metal_2018]. Aluminum, iron, and copper exposure can inhibit PP2A, contributing to tau pathology.
PP2A modulates neuroinflammation by regulating NF-κB and MAPK signaling pathways. Altered PP2A activity in microglia contributes to chronic neuroinflammation in AD and PD [@neuroinflammation_2015].
PP2A controls autophagy through dephosphorylation of mTORC1 substrates and ULK1 complex regulation. This connection is particularly relevant to protein aggregate clearance in neurodegenerative diseases [@autophagy_2016].
| Disease | PP2A Dysfunction | Mechanism |
|---|---|---|
| Alzheimer's Disease | ↓ Activity | Tau hyperphosphorylation, impaired dephosphorylation, methylation defects |
| Parkinson's Disease | ↓ Activity | Alpha-synuclein phosphorylation, mitochondrial dysfunction |
| FTLD | ↓ Activity | Tau hyperphosphorylation, aggregation |
| Cognitive Impairment | Variable | Synaptic plasticity deficits, methylation changes |
| PSP | ↓ Activity | Tau hyperphosphorylation at multiple sites |